SCHEMBL4336402

SCHEMBL4336402

CCOc1ccc(CC(OC(C)C)C(=O)O)cc1CCOC(=O)Nc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.44
NPSR1 Q6W5P4 1/20 0.43
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TSHR P16473 1/20 0.41
RECQL P46063 1/20 0.41
LMNA P02545 4/20 0.40
TP53 P04637 1/20 0.40
PPARA Q07869 2/20 0.40
MGLL Q99685 1/20 0.40
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 2/20 0.39
SLC2A1 P11166 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335108 0.92 L3MBTL1 (0.42) PPARGNPC1SMN1; SMN2LMNAPPARA
SCHEMBL4334521 0.91 MEN1 (0.48) PPARGNPC1RAB9ASMN1; SMN2TSHR
SCHEMBL4336960 0.91 LMNA (0.44) PPARGNPSR1NPC1RAB9ASMN1; SMN2
SCHEMBL4334226 0.90 NPSR1 (0.49) PPARGNPSR1NPC1RAB9ASMN1; SMN2
SCHEMBL13810553 0.90 PPARG (0.45) PPARGNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL4332348 0.89 PPARA (0.49) PPARGPPARA
SCHEMBL4327529 0.84 MAPT (0.42) PPARGSMN1; SMN2LMNAPPARAMAPT
SCHEMBL4334936 0.84 PPARA (0.49) PPARGNPSR1NPC1RAB9ASMN1; SMN2
SCHEMBL4333076 0.83 LMNA (0.45) PPARGNPSR1NPC1RAB9ASMN1; SMN2
SCHEMBL13810562 0.83 PPARG (0.42) PPARGNPC1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-20040102634-A1 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-05-27 US disclosed
EP-1380562-A1 CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102634-A1 Carboxylic acid derivative and salt thereof GPR119, IRS1, SLC5A1 PPARG 379/4885NPSR1 502/4885NPC1 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.